Anti Vegf Eylea 2mg denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti vegf eylea 2mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Eylea (aflibercept 2 mg) as Non-Formulary

A non-formulary denial means Eylea 2 mg is either not listed on your specific UHC plan's drug or medical benefit formulary, or it is listed at a tier that requires additional prior authorization or cost-sharing you have not yet satisfied. Formulary placement decisions are made at the plan level and can differ across UHC product lines (commercial, Medicare Advantage, Medicaid). This denial is administrative in origin and does not reflect a clinical judgment that the drug is inappropriate.

## Why This Denial Is Appealable

Even when a drug is non-formulary, plans are required to provide an exception process when the formulary alternative is contraindicated, has not been effective, or is otherwise clinically unsuitable for the individual patient. Under Part D rules (Medicare) and most commercial plan documents, a formulary exception must be granted if the prescriber documents that the non-formulary agent is medically necessary for reasons specific to the patient. The key is providing that individualized clinical justification — generic preference for a brand name is not enough, but a documented clinical distinction is.

## Your Federal Appeal Rights

• Formulary exception request: File this first — it is faster than a formal appeal and, if granted, avoids the appeal track entirely. Your prescriber must submit a statement explaining why a formulary alternative cannot be used.
• Internal appeal (Level 1): If the exception is denied, file a formal internal appeal under ERISA §503 or ACA §2719 procedures within the deadline on your denial letter.
• External review (Level 2, ACA §2719): Formulary exception denials that hinge on medical necessity are eligible for IRO review. File within approximately four months of the internal denial.
• Expedited exception/appeal: Available on a 24–72 hour timeline when the standard process would seriously jeopardize health.

## Documentation to Gather

1. Formulary alternatives tried — dates, durations, and documented outcomes or adverse effects for each formulary anti-VEGF agent UHC would prefer; or a clinical explanation of why each alternative is medically unsuitable. 2. Diagnosis and imaging — current chart notes, OCT reports, and visual acuity measurements establishing the diagnosis and disease activity. 3. Prescriber exception letter — a signed letter explaining, drug by drug, why the formulary alternatives are inadequate and why Eylea 2 mg is clinically required for this patient. 4. UHC formulary and exception policy — obtain both your plan's current formulary document and UHC's published formulary exception criteria; the prescriber's letter should map to those criteria explicitly. 5. FDA label — include the current FDA-approved labeling to confirm the indication is supported and the drug is not experimental.

## Criteria-Mapping Structure

For formulary exception appeals, the map takes a slightly different form: list each formulary alternative by name, then document the clinical finding (from the chart) that explains why that alternative is not appropriate. End with a direct statement matching the applicable exception criterion in UHC's policy. This parallel structure answers the only question the reviewer needs to resolve: is there a patient-specific reason the formulary alternative will not work?